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Abstract: BACKGROUND Many patients with non-alcoholic fatty liver disease (NAFLD) simultaneously
suffer from cardiovascular (CV) disease and often carry multiple CV risk factors. Several CV risk factors
are known to drive the progression of fibrosis in patients with NAFLD. OBJECTIVES To investigate
whether an established CV risk score, the Framingham risk score (FRS), is associated with the diagnosis
of NAFLD and the degree of fibrosis in an Austrian screening cohort for colorectal cancer. MATERIAL
AND METHODS In total, 1965 asymptomatic subjects (59 ± 10 years, 52% females, BMI 27.2 ± 4.9
kg/m2) were included in this study. The diagnosis of NAFLD was present if (1) significantly increased
echogenicity in relation to the renal parenchyma was present in ultrasound and (2) viral, autoimmune
or hereditary liver disease and excess alcohol consumption were excluded. The FRS (ten-year risk of
coronary heart disease) and NAFLD Fibrosis Score (NFS) were calculated for all patients. High CV risk
was defined as the highest FRS quartile (>10%). Both univariable and multivariable logistic regression
models were used to calculate associations of FRS with NAFLD and NFS. RESULTS Compared to
patients without NAFLD (n = 990), patients with NAFLD (n = 975) were older (60 ± 9 vs. 58 ± 10
years; p < 0.001), had higher BMI (29.6 ± 4.9 vs. 24.9 ± 3.6 kg/m2; p < 0.001) and suffered from
metabolic syndrome more frequently (33% vs. 7%; p < 0.001). Cardiovascular risk as assessed by FRS
was higher in the NAFLD-group (8.7 ± 6.4 vs. 5.4 ± 5.2%; p < 0.001). A one-percentage-point increase of
FRS was independently associated with NAFLD (OR 1.04, 95%CI 1.02-1.07; p < 0.001) after correction
for relevant confounders in multivariable logistic regression. In patients with NAFLD, NFS correlated
with FRS (r = 0.29; p < 0.001), and FRS was highest in patients with significant fibrosis (F3-4; 11.7 ± 5.4)
compared to patients with intermediate results (10.9 ± 6.3) and those in which advanced fibrosis could
be ruled-out (F0-2, 7.8 ± 5.9, p < 0.001). A one-point-increase of NFS was an independent predictor of
high-risk FRS after correction for sex, age, and concomitant diagnosis of metabolic syndrome (OR 1.30,
95%CI 1.09-1.54; p = 0.003). CONCLUSION The presence of NAFLD might independently improve
prediction of long-term risk for CV disease and the diagnosis of NAFLD might be a clinically relevant
piece in the puzzle of predicting long-term CV outcomes. Due to the significant overlap of advanced
NAFLD and high CV risk, aggressive treatment of established CV risk factors could improve prognosis
in these patients.
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Abstract: Background: Many patients with non-alcoholic fatty liver disease (NAFLD) simultaneously
suffer from cardiovascular (CV) disease and often carry multiple CV risk factors. Several CV risk factors
are known to drive the progression of fibrosis in patients with NAFLD. Objectives: To investigate whether
an established CV risk score, the Framingham risk score (FRS), is associated with the diagnosis of
NAFLD and the degree of fibrosis in an Austrian screening cohort for colorectal cancer. Material and
Methods: In total, 1965 asymptomatic subjects (59 ± 10 years, 52% females, BMI 27.2 ± 4.9 kg/m2) were
included in this study. The diagnosis of NAFLD was present if (1) significantly increased echogenicity
in relation to the renal parenchyma was present in ultrasound and (2) viral, autoimmune or hereditary
liver disease and excess alcohol consumption were excluded. The FRS (ten-year risk of coronary heart
disease) and NAFLD Fibrosis Score (NFS) were calculated for all patients. High CV risk was defined
as the highest FRS quartile (>10%). Both univariable and multivariable logistic regression models
were used to calculate associations of FRS with NAFLD and NFS. Results: Compared to patients
without NAFLD (n = 990), patients with NAFLD (n = 975) were older (60 ± 9 vs. 58 ± 10 years;
p < 0.001), had higher BMI (29.6 ± 4.9 vs. 24.9 ± 3.6 kg/m2; p < 0.001) and suffered from metabolic
syndrome more frequently (33% vs. 7%; p < 0.001). Cardiovascular risk as assessed by FRS was
higher in the NAFLD-group (8.7 ± 6.4 vs. 5.4 ± 5.2%; p < 0.001). A one-percentage-point increase of
FRS was independently associated with NAFLD (OR 1.04, 95%CI 1.02–1.07; p < 0.001) after correction
for relevant confounders in multivariable logistic regression. In patients with NAFLD, NFS correlated
with FRS (r = 0.29; p < 0.001), and FRS was highest in patients with significant fibrosis (F3-4; 11.7 ± 5.4)
compared to patients with intermediate results (10.9 ± 6.3) and those in which advanced fibrosis could
be ruled-out (F0-2, 7.8 ± 5.9, p < 0.001). A one-point-increase of NFS was an independent predictor
of high-risk FRS after correction for sex, age, and concomitant diagnosis of metabolic syndrome
(OR 1.30, 95%CI 1.09–1.54; p = 0.003). Conclusion: The presence of NAFLD might independently
improve prediction of long-term risk for CV disease and the diagnosis of NAFLD might be a clinically
relevant piece in the puzzle of predicting long-term CV outcomes. Due to the significant overlap
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of advanced NAFLD and high CV risk, aggressive treatment of established CV risk factors could
improve prognosis in these patients.
Keywords: NAFLD; cardiovascular risk; Framingham risk score; CVD; risk prediction; secondary
prevention; primary prevention; metabolic syndrome; NAFLD fibrosis score
1. Introduction
With a constant increase in the incidence of metabolic syndrome, the prevalence of non-alcoholic
fatty liver disease (NAFLD) is estimated to be around 25% in Europe. A steep rise in the prevalence
of NAFLD from 15% in 2005 to 25% in 2010 has been observed [1]. This increase mirrors obesity
rates, which nearly tripled since 1975 and reached epidemic levels [2]. Components of the metabolic
syndrome such as hypertension, dyslipidemia, dysglycemia, and abdominal obesity are established
risk factors for NAFLD [3]. Since they have also been established as risk factors for CVD, patients
frequently suffer from both conditions.
CVD is a leading cause of death worldwide both in the general population and patients with
NAFLD [4–6]. NAFLD is independently associated with several markers of subclinical atherosclerosis
such as coronary artery calcification, impaired flow-mediated vasodilation, arterial stiffness, carotid
artery inflammation and thickening of carotid intima-media as well as left ventricular hypertrophy
and diastolic dysfunction [7,8]. Importantly, some of these studies suggest an association of these
two disease entities independent from traditional risk factors. Several lines of evidence suggest that
NAFLD may be causally and independently involved in CVD pathogenesis [9,10].
Different possible pathophysiological pathways link NAFLD with CVD [11]. Markers of inflammation
such as cytokines, CRP, or interleukin-6 are overexpressed in these patients and also correlate with
a higher degree of liver fibrosis [12]. Furthermore, patients with hepatic steatosis show elevated
levels of pro-coagulant factors such as fibrinogen, von Willebrand factor and plasminogen activator
inhibitor-1 [13]. Additionally, hepatic insulin resistance and atherogenic dyslipidemia seem to contribute
to the development of CVD [14]. These mechanisms are possible explanations for the fact that the severity
of NAFLD, especially if progressed to non-alcoholic steatohepatitis (NASH) with fibrosis, additionally
contributes to CV risk [15].
In our study, we examined the prevalence of NAFLD in an Austrian screening cohort for colorectal
cancer (SAKKOPI). An established non-invasive estimate of fibrosis severity i.e., the NAFLD fibrosis
score (NFS) was calculated and the relation of fibrosis with CV risk as assessed by the Framingham
Risk Score (FRS) evaluated.
2. Methods
2.1. Study Subjects
The study cohort consisted of 1965 Caucasians undergoing routine screening colonoscopy at a
single center in Austria. All Patients were recruited between 2010 and 2014. Informed consent was
obtained, and the study was approved by the local ethics committee (Ethikkommission des Landes
Salzburg, approval no. 415-E/1262/2-2010).
2.2. Assessment
As previously described, participants were examined on two consecutive days [16]. On the day of
admission, venous blood was drawn after an overnight fast. A whole blood count, kidney and liver
tests, lipids, CRP, as well as hemoglobin A1c, an oral glucose tolerance test, and insulin levels were
measured. The participants completed a detailed questionnaire including past medical history, current
medical regimen, family history, smoking history (“never smokers”, “former smokers”, or “current
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smokers”) dietary habits and physical activity. A standard physical examination including blood
pressure, height, weight, and waist circumference) was performed. Importantly, all patients underwent
abdominal ultrasonography. The liver was considered normal if echogenicity was similar to the renal
parenchyma. If areas showed a significantly increased echogenicity compared to the renal parenchyma,
the liver was considered steatotic. On the second day, all subjects underwent complete colonoscopy.
2.3. Definitions
The diagnosis of NAFLD was made after exclusion of viral, autoimmune and hereditary liver
diseases (Wilson disease, hereditary haemochromatosis, alpha-1 antitrypsin deficiency) and excess
daily alcohol consumption ≥30 g for men and ≥20 g for women according to the European clinical
practice guidelines for the management of NAFLD [17]. NAFLD fibrosis score (NFS) was calculated
as previously described [18]. Briefly, NFS (age, body mass index (BMI), presence of impaired fasting
glucose or diabetes, aspartate-aminotransferase (AST), alanine-aminotransferase (AST), platelets and
albumin) was used to stratify patients according to their risk of significant fibrosis. Specifically, patients
with a NFS < −1.455 were graded as F0-2, those with NFS > 0.676 as “F3-4”, and patients with a NFS
between −1.455 and 0.676 as “intermediate”.
Metabolic syndrome was diagnosed when three or more of the following criteria were met [19]:
fasting blood glucose level ≥100 mg/dL or antidiabetic therapy, waist circumference >102 cm in males
and >88 cm in females, blood pressure ≥130/85 mmHg or current antihypertensive treatment, plasma
triglycerides ≥150 mg/dL, and plasma HDL <40 mg/dL in males and <50 mg/dL in females.
2.4. Cardiovascular Risk Assessment
We evaluated patients for cardiovascular disease applying the Framingham Risk Score (FRS) [20].
Although the FRS is not validated in subjects with diabetes (T2DM), we did include subjects with
T2DM in our analysis and performed a separate analysis, excluding all subjects with T2DM. Since
results were not changed when subjects with T2DM were excluded, we report the results including
T2DM to allow for greater generalizability of our results.
2.5. Statistical Analysis
Continuous variables are expressed as mean (±standard deviation) and compared using t-test
or ANOVA. Categorical data are expressed as numbers (percentage). Chi-square test was applied
to calculate differences between groups. Both univariable and multivariable logistic regression was
used to evaluate associations of FRS with NAFLD and NFS with CV risk. For multivariable logistic
regression, elimination criteria was a p-value of < 0.10 following backward elimination. Variables were
included in the multivariable model based on literature. All variables included in the multivariable
models evidenced a univariable association at a p-value of p < 0.05. A p-value of < 0.05 was considered
statistically significant. SPSS version 22.0 (IBM, USA) was used for statistical analyses.
3. Results
3.1. Analysis of the Total Study Cohort, NAFLD versus Non-NAFLD Patients
Overall, 49.6% (n = 975) of patients had NAFLD as defined by hepatic steatosis in ultrasound,
while 990 patients (50.4%) did not have NAFLD. NAFLD patients were older (60 ± 9 vs. 58 ± 10 years;
p < 0.001), evidenced higher BMI (29.6 ± 4.9 vs. 24.9 ± 3.6 kg/m2; p < 0.001) and more frequently
fulfilled criteria for metabolic syndrome (33% vs. 7%; p < 0.001). Characteristics of NAFLD versus
non-NAFLD patients are shown in Table 1.
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Table 1. Baseline characteristics of patients without (n = 990) and with (n = 975) non-alcoholic fatty
liver disease (NAFLD).
No NAFLD NAFLD Total Cohort
p-Value
n = 990 n = 975 n = 1965
Female 61% 43% 52% <0.001
Age (years) 58 (10) 60 (9) 59 (10) <0.001
Systolic RR (mmHg) 128 (18) 135 (19) 131 (18) <0.001
Diastolic RR (mmhg) 79 (10) 83 (11) 81 (10) <0.001
BMI (kg/m2) 25 (4) 26 (5) 27 (4) <0.001
Waist circumference (cm) 90 (11) 105 (12) 97 (11) <0.001
Waist to hip ratio 1 (0.1) 1 (0.1) 1 (0.1) <0.001
Bilirubine (mg/dL) 0.72 (0.4) 0.73 (0.4) 0.72 (0.4) 0.4
GGT (U/L) 31 (46) 48 (71) 40 (46) <0.001
AST (U/L) 22 (12) 26 (18) 24 (12) <0.001
INR 1.0 (0.1) 1.0 (0.1) 1.0 (0.1) 0.24
Total cholesterol (mg/dL) 219 (40) 217 (44) 218 (40) 0.25
HDL (mg/dL) 67 (18) 56 (16) 62 (18) <0.001
LDL (mg/dL) 137 (36) 142 (39) 139 (36) 0.02
Triglycerices (mg/dL) 101 (51) 145 (85) 123 (51) <0.001
Thrombocytes (G/L) 236 (66) 227 (65) 232 (66) 0.001
Fasting glucose (mg/dL) 97 (15) 109 (30) 103 (15) <0.001
HbA1c (%) 5.6 (0.5) 5.9 (0.8) 5.8 (0.5) <0.001
Metabolic syndrome 7% 33% 20% <0.001
T2DM 9% 24% 16% <0.001
Current smoker 19% 17% 20% 0.48
Medication
ASS 11% 17% 14% 0.001
Statin 15% 23% 19% <0.001
ACE-I/ARB 13% 27% 20% <0.001
Metformin 2% 8% 5% <0.001
CV risk score
FRS 5.41 (5.20) 8.71 (6.38) 7.05 (5.20) <0.001
FRS 0-2% 41% 19% 30% <0.001
FRS >2–5% 21% 19% 20%
FRS >5–10% 22% 30% 25%
FRS >10% 16% 33% 24%
NAFLD: Non-alcoholic fatty liver disease; NFS: NAFLD fibrosis score; FRS: Framingham Risk Score; RR: blood
pressure; GGT: gamma-glutamyl-transferase; AST: Aspartate transaminase; INR: International normalized ratio;
HDL: High-density lipoprotein; LDL: Low-density lipoprotein; HbA1c: Glycated hemoglobin; T2DM: type 2
diabetes mellitus; ASS: acetylsalicylic acid; CV: cardiovascular; OR: odds ratio.
CV risk assessed by FRS was higher in the NAFLD-group (8.7 ± 6.4 vs. 5.4 ± 5.2%; p < 0.001).
After allocation of subjects to FRS into risk quartiles (Q1: FRS 0%–2%; Q2: FRS 2%–5%; Q3: FRS
5%–10%, Q4: FRS > 10%), patients with NAFLD more often were in the Q4-FRS group (33% vs. 16%;
p < 0.001) compared to non-NAFLD patients.
In univariable logistic regression, this relationship corresponded to an increase of OR of 1.11,
(95%CI 1.09–1.13; p < 0.001) in the likelihood for NAFLD per one-percentage-point increase of FRS.
This association remained significant after correction for age, sex and metabolic syndrome (OR, 1.04
95%CI 1.02–1.07; p < 0.001) in a multivariable model (Table 2). In an additional sensitivity analysis,
a one-percentage-point increase of FRS remained associated with an increased likelihood for NAFLD
both in males (OR 1.08, 95%CI 1.06–1.11; p < 0.001) and females (OR 1.13, 95%CI 1.09–1.18; p < 0.001).
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Table 2. Univariable and multivariable associations with the presence of NAFLD.
Univariable Multivariable
OR 95%CI p-Value OR 95%CI p-Value
Age 1.03 1.02–1.04 <0.001 1.010 0.998–1.023 0.11
Female gender 0.48 0.40–0.58 <0.001 0.68 0.54–0.86 0.001
Metabolic syndrome 6.08 4.63–7.99 <0.001 5.02 3.77–6.70 <0.001
FRS 1.11 1.09–1.13 <0.001 1.06 1.04–1.08 <0.001
3.2. Analysis of Patients with NAFLD
Patients with NAFLD were grouped according to their NFS into F0-F2 (n = 604), intermediate
(n = 138) and F3-4 (n = 10). The characteristics of patients according to their NFS are shown in Table 3.
Over the whole NAFLD cohort, NFS correlated with FRS (r = 0.29; p < 0.001), and FRS was highest in
the F3-4 group (11.7 ± 5.4%; p < 0.001 vs. F0-F2) compared to the intermediate (10.9 ± 6.3%) and the
F0-F2 group (7.8 ± 5.9%). When grouping intermediate and F3-4 into an “at-risk” group (due to small
sample size in F3-4), the significant differences between F0-2 essentially persisted (Table 4).
In univariable logistic regression, a one-point increase of NFS was associated with a higher
likelihood of high-risk FRS (OR 1.60, 95%CI 1.41–1.83; p < 0.001). NFS remained an independent
predictor of Q4-FRS after correction for sex, age, and concomitant diagnosis of metabolic syndrome
(OR 1.30, 95%CI 1.09–1.54; p = 0.003). In a sensitivity analysis in both males (OR 1.84, 95%CI 1.54–2.20;
p < 0.001) and females (OR 2.06, 95%CI 1.52–2.78; p < 0.001) a one-point increase of NFS remained
associated with high-quartile FRS. Univariable and multivariable significant associations of age, female
gender, metabolic syndrome, and FRS with the presence of high risk NFS are depicted in Table 5.
Table 3. Baseline characteristics of patients according to their NAFLD Fibrosis Score (NFS) score: F0-F2
(n = 604), intermediate (n = 138) and F3-F4 (n = 10).
F0-F2 Intermediate F3-F4
n = 604 n = 138 n = 10
Mean SD Mean SD Mean SD p-Value
Female 36% 43% 50% 0.80
Age (years) 59 9 66 8 67 9 <0.001
Systolic RR (mmHg) 134 18 139 19 148 26 <0.001
Diastolic RR (mmhg) 82 11 85 12 85 12 0.07
BMI (kg/m2) 29 4 33 6 35 4 <0.001
Waist circumference (cm) 103 11 111 12 115 14 <0.001
Waist to hip ratio 0.96 0 0.97 0 0.97 0 0.23
Bilirubine (mg/dL) 0.70 0 0.80 1 1.57 1 <0.001
GGT (U/L) 48 76 53 70 115 145 0.02
AST (U/L) 25 15 30 24 55 61 <0.001
INR 0.99 0 1.02 0 1.17 0 <0.001
Total cholesterol (mg/dL) 221 44 202 42 221 52 <0.001
HDL (mg/dL 57 16 53 13 57 13 0.03
LDL (mg/dL) 145 40 130 37 142 41 <0.001
Triglycerices (mg/dL) 145 84 147 101 142 68 0.97
Thrombocytes (G/L) 243 62 176 52 128 88 <0.001
Fasting glucose (mg/dL) 107 28 115 28 97 16 0.01
HbA1c (%) 5.9 1 6.0 1 5.6 0 0.08
Metabolic syndrome 30% 43% 40% 0.01
T2DM 20% 44% 20% <0.001
Current Smoker 19% 6% 0% 0.02
Medication
ASS 24% 31% 13% 0.21
Statin 24% 31% 13% 0.21
ACE-I/ARB 22% 38% 20% 0.02
Metformin 8% 10% 0% 0.42
FRS 7.83 5.92 10.87 6.29 11.70 5.44 <0.001
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Table 4. Baseline characteristics of patients according to their NFS score: F0-F2 (n = 604), and
intermediate or F3-F4 (n = 148).
F0-F2 Intermediate or F3-F4
n = 604 n = 148
p-Value
Female 41% 43% 0.64
Age (years) 59 (9) 66 (9) <0.001
Systolic RR (mmHg) 134 (18) 140 (18) <0.001
Diastolic RR (mmhg) 82 (11) 85 (11) 0.02
BMI (kg/m2) 29 (4) 33 (4) <0.001
Waist circumference (cm) 103 (11) 111 (11) <0.001
Waist to hip ratio 1 (0) 1 (0) 0.09
Bilirubine (mg/dL) 1 (0) 1 (0) <0.001
GGT (U/L) 48 (76) 57 (76) 0.16
AST (U/L) 25 (15) 32 (15) <0.001
INR 0.99 (0.07) 1.03 (0.07) <0.001
Total cholesterol (mg/dL) 221 (44) 203 (44) <0.001
HDL (mg/dL 57 (16) 53 (16) 0.01
LDL (mg/dL) 145 (40) 131 (40) <0.001
Triglycerices (mg/dL) 145 (84) 147 (84) 0.87
Thrombocytes (G/L) 243 (62) 173 (62) <0.001
Fasting glucose (mg/dL) 107 (28) 113 (28) 0.01
HbA1c (%) 5.9 (0.7) 6.0 (0.7) 0.12
Metabolic syndrome 30% 43% 0.003
T2DM 20% 40% <0.001
Current Smoker 19% 6% 0.003
Medication
ASS 16% 21% 0.11
Statin 24% 30% 0.20
ACE-I/ARB 22% 37% 0.01
Metformin 8% 10% 0.39
FRS 7.83 (5.92) 10.92 (5.92) <0.001
Table 5. Univariable and multivariable associations with the presence of high risk NFS score.
Univariable Multivariable
OR 95%CI p-Value OR 95%CI p-Value
Age 1.11 1.09–1.13 <0.001 1.17 1.14–1.21 <0.001
Female gender 0.15 0.10–0.21 <0.001 0.02 0.01–0.04 <0.001
Metabolic syndrome 2.46 1.86–3.26 <0.001 4.15 2.64–6.55 <0.001
FRS 1.60 1.41–1.83 <0.001 1.30 1.09–1.54 0.003
4. Discussion
Our study confirms that there is a “silent epidemic” of NAFLD. In the present cohort of
asymptomatic individuals undergoing colonoscopy screening between 50 and 75 years of age, around
50% were diagnosed with NAFLD. In total, 14.2% of the screened patients were categorized as being
intermediate and 1% of patients were at high risk for advanced fibrosis by the NFS. Importantly,
patients with NAFLD had higher CV risk as defined by the FRS compared to patients without NAFLD.
Finally, the CV risk was highest in patients with highest NFS scores.
The NFS does not only predict the risk for advanced liver fibrosis, but also CV risk. Interestingly,
in a post-hoc analysis of the IMPROVE-IT trial the NFS identified patients who were at the highest risk
for recurrent cardiovascular events. The IMPROVE-IT compared statin therapy alone to the add-on of
ezetimibe in post ACS patients [21]. In this trial, higher NFS identified patients more likely to benefit
from aggressive lipid-lowering therapy. Thus, although the IMPROVE-IT trial was not designed to
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assess the link between NAFLD and ACS, it offers important data on the potential link between fatty
liver severity and atherosclerosis [21].
The most obvious link between CV risk and NFS is the fact that this score is constituted of factors
like age, BMI, ALT, AST, platelets, albumin, and the presence or absence of diabetes, all of which reflect
metabolic and inflammatory processes. Of note, inflammation and fibrosis are hallmarks of both liver
and cardiovascular disease [18] and may therefore indicate common systemic mechanisms.
In our analysis, NAFLD was an independent risk indicator for CV risk. This is in concordance
with a meta-analysis of pooled studies from European, Asian, and American countries suggesting an
independent association of NAFLD with CV risk [10]. However, a British study including 17.7 million
patients found that the diagnosis of NAFLD was not associated with increased risk for acute myocardial
infarction or stroke after adjustment for established CV risk factors [22]. Nevertheless, in another
meta-analysis of Targher et al., patients with NAFLD evidenced an increased risk of fatal and non-fatal
CV disease [23]. Although the link between NAFLD and CV risk seems intuitive, the effect on CV
mortality or events has not been demonstrated. Also, a role for a specific medical treatment for
NAFLD in preventing CV events and mortality beyond lifestyle advice and current CV guidelines is
not established [24,25]. The data in this manuscript suggests an independent relationship of CV risk
and NAFLD in an Austrian cohort. Specific management strategies may be considered based on this
evidence to improve liver outcomes in CV patients and CV outcomes in liver patients.
4.1. CV Risk Assessment for NALFD Patients
Considering the Joint Clinical Practice Guidelines of EASL-EASD-EASO for the management of
NAFLD patients [17], a non-invasive test should be used as the first screening tool to assess disease
severity. Depending on the result, patients can be graded into low, intermediate and high risk with
regard to advanced fibrosis. For patients in the low risk group, their individual cardiovascular risk
should be assessed by risk scores as for example by the FRS. Target goals for risk factors, e.g., for blood
pressure, LDL levels, body weight or blood glucose should be treated according to primary prevention
guidelines [25].
Patients with intermediate and high risk for advanced fibrosis should be referred to a hepatologist.
In patients with advanced fibrosis stage or even cirrhosis CV risk should be assessed by a cardiologist as
described in by Choudhary and Duseja [26]. All other patients should be clinically assessed, stratified
by a CV risk score and should be managed according to respective prevention guidelines [25] (Figure 1).
 
Figure 1. Cardiovascular (CV) assessment algorithm in patients with diagnosed NAFLD.
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4.2. Screening for NAFLD in CV Patients
For patients after an CV event or at with a high CV risk we suggest the following approach to
detect NAFLD. As a screening test the NFS could be calculated. For patients with low risk for advanced
fibrosis, lifestyle modification changes could be recommended. Patients with an intermediate risk could
be referred to a liver ultrasound exam and to a hepatologist with expertise in transient elastography.
If these exams show no fibrosis or a low stage of fibrosis they should be managed as patients in the low
risk group. For patients with intermediate risk in the NFS and advanced fibrosis or cirrhosis in the
further exams as well as for patients with a high risk NFS score a hepatologist should be consulted.
We are aware, that NFS was developed to estimate fibrosis in the presence of NAFLD. However, we
here propose NFS as cheap and non-invasive “screening tool” for NAFLD in patients after an CV
event or with a high CV risk. All patients should be treated according to the current guidelines of the
European Society of Cardiology [24] (Figure 2).
 
Figure 2. Liver assessment in patients with high cardiovascular risk or with a cardiovascular event in
the past medical history.
5. Limitations
This study is a post-hoc analysis of a single-center prospective register and the results remain
thesis-generating. However, these data mirror a real-world Austrian population and indicate a high
prevalence of undetected NAFLD in the general population. Although this study cannot provide
longitudinal CV outcome data, we provide data from a carefully characterized cohort in a cross-sectional
study. Another limitation of this study is the linearity of the models especially in using a high number
of contributing factors, an assumption that is implicit due to the design of the study.
Furthermore, ultrasound and not liver transient elastography was used to diagnose NAFLD.
Finally, clinical data and established surrogate risk scores for calculation of the CV risk as well as the
determination of the degree of liver fibrosis by non-invasive scores were used, even though there are
other but more expensive and sometime even more invasive methods available to determine CV risk or
liver fibroses such as magnetic resonance imaging, liver biopsy, liver transient elastography, vascular
ultrasound, or coronary calcium scoring.
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6. Conclusions
The presence of NAFLD might independently predict long-term risk for CV disease. Therefore,
patients with high risk for or known CV events should be screened for the presence of NAFLD and
risk scores should be routinely applied. Non-invasive risk scores for CV risk and fibrosis could help
to facilitate and optimize management of patients with NAFLD with increased CV risk. The care
for patients with both NAFLD and CV disease is challenging and due to the vast overlap of patients
screening for liver disease in CV patients as well as screening for NAFLD in CV patients seems
reasonable [26]. Cardiologists and hepatologists should team up in the treatment of their patients [27].
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